Real-estate lessor in FR. Official registry identity and a deliberately broad sector benchmark on one indexed company profile.
DAMIPHARM is shown here as a public net-asset reference from filed balance sheets. It is not an earnings-multiple valuation; owner or advisor data is needed for debt, asset quality, leases and marketability adjustments.
Broad benchmark based on comparable companies in this sector — not a company-specific appraisalCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
This is a public asset-reference range, not an earnings-multiple valuation or a final transaction value. More accuracy requires owner or advisor context.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Operating as a real-estate lessor, DAMIPHARM is registered in France. The company was founded in 1997, incorporated as a 6540.
DAMIPHARM is listed in French National Business Register (RNE/INPI) under registry number 411614282.
Companies in this NACE 68.20 band file annual accounts with INPI.
DAMIPHARM's public range is a deliberately broad p10-p90 sector benchmark based on at least 30 comparable companies with stronger filed or size evidence. It is not a company-specific appraisal, midpoint, sale price, offer, or recommendation.
The benchmark is refreshed from governed Tier A/B peer distributions and is labelled separately from the source facts for DAMIPHARM.
DAMIPHARM was founded in 1997 and is registered with French National Business Register (RNE/INPI), incorporated as a 6540.
DAMIPHARM is registered under NACE 68.20: NACE 68.20. That places the business within the French cluster for this activity.
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for DAMIPHARM may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
